Cypress acquires Lupus monitoring technology
USA-based Cypress Bioscience has acquired the firm Cellatope's (formerly Stagemark) CB-CAP technology platform that uses cell-bound complement activation products to diagnose and monitor debilitating autoimmune disorders, including systemic lupus erythematosus.
Under the terms of the agreement, Cypress will make a $2.0-million cash payment to Cellatope, as well as an additional $3.0-million potential milestone associated with the commercial development of the CB-CAP monitoring technology for Lupus.
Cypress plans to complete the development program and add Lupus personalized medicine services to its current Avise product line, which includes tests for diagnosis, prognosis and the monitoring treatment of rheumatoid arthritis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze